

Media release

14.2.2008

Shares in HBM BioVentures (HBMN) open at CHF 80.50

Shares in HBM BioVentures were traded in the investment companies segment of the SWX Swiss Exchange for the first time today. Trading on the SWX opened at CHF 80.50 and increased to CHF 83.00 by noon. The listing comprises all outstanding 11,262,859 registered shares and the formal listing of 1,600,000 registered shares from the conditional capital.

HBM BioVentures invests globally in the human medicine / biotechnology and medical technology sectors. As a venture capital company it manages a mature, widely diversified portfolio of private and emerging small-cap public companies. The company gives investors access to this newly created investment segment and is thus an alternative to investments in listed pharmaceutical companies. HBM BioVentures is an active, long-term investor in research and development which finances, accompanies and supports portfolio companies as a key partner.

Should you have any questions, please feel free to contact Werner Vogt, Spokesman SWX Swiss Exchange.

Phone: +41(0)58 854 26 75

Fax: +41(0)58 854 27 10

E-mail: pressoffice@swx.com

SWX Swiss Exchange

The SWX Swiss Exchange is one of the world's leading and most technologically advanced securities exchanges. It provides customers with first-rate securities exchange services and brings together participants, issuers and investors in an efficient and transparent marketplace. In addition to the broad palette of products it offers, the SWX Swiss Exchange's integrated, fully automatic trading, clearing and settlement system is indeed convincing: at the click of a mouse, orders are executed, cleared, settled and confirmed.

www.swx.com